Novavax, Inc. (NVAX) Posts Q2 Loss of 8c/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. AMZN
10. LEN

Go back to Novavax, Inc. (NVAX) Posts Q2 Loss of 8c/Share

Novavax Reports Second-Quarter 2014 Financial Results

August 6, 2014 4:19 PM EDT

GAITHERSBURG, Md., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today reported its financial results for the second quarter and six months ended June 30, 2014.

Novavax Corporate Highlights

Second Quarter Achievements:

- Delivered positive top-line data from a dose-confirmatory Phase 2 clinical trial of its RSV F-protein vaccine candidate in 720 women of childbearing age, including a key finding that the highest levels of Palivizumab-competing... More